ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Addex Therapeutics Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026

$2.89+0.13 (+4.71%)

Close on Oct 19, 2026

Addex Therapeutics Ltd. income statement

Annual QuarterlyTTM

CHF USD

Millions of CHF, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	0.03	0.40	1.61	1.42	2.92	3.61	2.76	6.04	–
Research & Development	0.67	0.85	1.19	8.24	13	10	12	4.92	2.63
Operating Expenses	2.99	3.17	3.86	12	19	16	17	8.13	3.73
Operating Income	-2.81	-2.76	-2.24	-11	-16	-12	-15	-1.42	-3.24
Interest Expense	0.02	0.00	0.32	0.29	0.06	0.65	0.21	0.22	0.05
Interest & Investment Income	–	0.03	0.06	0.03	0.22	0.04	0.04	–	–
Pretax Income	-6.84	-4.91	-2.50	-11	-15	-13	-15	-1.64	-3.28
Income Tax Expense	0	0	0	0	0	0	0	0	–
Income from Continuing Operations	-6.84	-4.91	-2.50	-11	–	–	–	–	–
Income from Discontinued Operations	0.11	12	-8.06	-10	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-6.73	7.06	-11	-21	-15	-13	-15	-1.64	-3.28
Net Income to Common	-6.73	7.06	-11	-21	-15	-13	-15	-1.64	-3.28
EPS (Basic)(per share)	-0.06	0.07	-0.14	-0.46	-0.45	-0.48	-0.56	-0.07	-0.25
EPS (Diluted)(per share)	-0.06	0.07	-0.14	-0.46	-0.45	-0.48	-0.56	-0.07	-0.25
Shares Outstanding (Basic, Weighted)(shares)	107	98	74	45	34	27	26	23	13
Shares Outstanding (Diluted, Weighted)(shares)	107	98	74	45	34	27	26	23	13

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -9390.8%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 0.76
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 56.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.